Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

Shiro Suzuki; Kiyosumi Shibata; Fumitaka Kikkawa; Tetsuya Nakatsura
February 2014
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • p53: son rôle dans les mécanismes de résistance. Sait-on s’en servir en pratique cancérologique en 2005? Cals, L.; Maille, N.; Sohn, C.; Tchiknavorian, X.; Poirot, F. // Oncologie;nov2005, Vol. 7 Issue 7, p574 

    p53 is an important protein in repairing cell DNA or triggering apoptosis after an injury. It is one of the most investigated molecular markers in cancer; many papers have been published about this biomarker. Nevertheless, the level of evidence for the use of p53 to predict recurrence,...

  • Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Suzuki, Shiro; Sakata, Jun; Utsumi, Fumi; Sekiya, Ryuichiro; Kajiyama, Hiroaki; Shibata, Kiyosumi; Kikkawa, Fumitaka; Nakatsura, Tetsuya // OncoImmunology;2016, Vol. 5 Issue 11, pN.PAG 

    Compared with other epithelial ovarian carcinoma subtypes, ovarian clear cell carcinoma (OCCC) has been recognized to show chemoresistance. Therefore, new treatment modalities are required for patients with OCCC that is refractory to chemotherapy. The carcinoembryonic antigen glypican-3 (GPC3)...

  • Sorafenib.  // Reactions Weekly;Apr2015, Vol. 1545 Issue 1, p222 

    The article discusses a study published in the January 2014 issue of "Cancer Biology and Therapy" that examined two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

  • A comparison of clinico-pathologic characteristics of patients with serous and clear cell carcinoma of the uterus. Üreyen, Işın; Karalok, Alper; Cırık, Derya Akdağ; Taşçı, Tolga; Türkmen, Osman; Cömert, Günsü Kimyon; Boran, Nurettin; Tulunay, Gökhan; Turan, Taner // Journal of Turkish Society of Obstetrics & Gynecology;Sep2016, Vol. 13 Issue 3, p137 

    Objective: Serous carcinoma and clear cell carcinomas account for 10% and 3% of endometrial cancers but are responsible for 39% and 8% of cancer deaths, respectively. In this study, we aimed to compare serous carcinoma and clear cell carcinoma regarding the surgico-pathologic and clinical...

  • Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. Hisae Iinuma; Ryoji Fukushima; Tsuyoshi Inaba; Junko Tamura; Taisuke Inoue; Etsushi Ogawa; Masahiro Horikawa; Yoshibumi Ikeda; Noriyuki Matsutani; Kazuyoshi Takeda; Koji Yoshida; Takuya Tsunoda; Tadashi Ikeda; Yusuke Nakamura; Kota Okinaga // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Chemoradiation therapy (CRT) has been widely used for unresectable esophageal squamous cell carcinoma (ESCC) patients. However, many patients develop local recurrence after CRT. In this study, we hypothesized that the immunotherapy by peptide vaccine may be effective for the...

  • The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Masanori Kobayashi; Asako Chiba; Hiromi Izawa; Eri Yanagida; Masato Okamoto; Shigetaka Shimodaira; Yoshikazu Yonemitsu; Yuta Shibamoto; Noboru Suzuki; Masaki Nagaya // Journal of Ovarian Research;2014, Vol. 7 Issue 1, p1 

    Background Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)- based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of...

  • Tumor Vaccines: A Role in Preventing Recurrence in Melanoma? Sabel, M.S.; Sondak, V.K. // American Journal of Clinical Dermatology;2002, Vol. 3 Issue 9, p609 

    Patients presenting with thick primary melanomas or those with regional nodal metastases have a high risk of recurrence after surgery alone. Chemotherapy has limited efficacy in the adjuvant setting, and while the use of high-dose interferon in the adjuvant setting has been reported to improve...

  • Evaluation of p53, PTEN and β-catenin Immunoexpressions in Primary Ovarian Epithelial Tumors. Aslani, Fatemeh Sari; Momeni, Azarmidokht; Momtahan, Mozhdeh; Jahromi, Mozhgan Akbarzadeh; Dehghanian, Amir Reza; Motevali, Dorna // Middle East Journal of Cancer;Jul2015, Vol. 6 Issue 3, p135 

    Background: Ovarian cancer comprises a heterogeneous group of neoplasms. The prognosis cannot be predicted by histopathologic examination alone. The aim of this study is to evaluate p53, PTEN, and β-catenin expressions in primary ovarian carcinomas in an attempt to find a possible...

  • Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma. Nishida, Masato; Tsunoda, Hajime; Ichikawa, Yoshihito; Yoshikawa, Hiroyuki // International Journal of Clinical Oncology;Oct2004, Vol. 9 Issue 5, p403 

    A 55-year-old multiparous woman was diagnosed with stage IIIc ovarian clear cell carcinoma. Three years after the first surgery and adjuvant chemotherapy with irinotecan hydrochloride and mitomycin C, she developed common iliac lymph node recurrence. Two cycles of chemotherapy with irinotecan...

  • Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report. Eriko Takatori; Tadahiro Shoji; Yuki Miura; Anna Takada; Satoshi Takeuchi; Toru Sugiyama // OncoTargets & Therapy;2014, Vol. 7, p165 

    A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics